Enterprise Value
17.73M
Cash
4.391M
Avg Qtr Burn
-5.044M
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
1.89%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Paxalisib (GDC-0084) (PI3K pathway) Details Glioblastoma | Phase 2/3 Interim update | |
Cantrixil (TRX-E-002-1) Details Ovarian cancer | Failed Discontinued |